HOUSE BILL 996
J1 5lr2596
By: Delegate Bhandari Delegates Bhandari, Pena–Melnyk, Cullison, Alston,
Bagnall, Chisholm, Guzzone, Hill, Hutchinson, S. Johnson, Kaiser, Kerr,
Kipke, Lopez, Martinez, M. Morgan, Reilly, Rosenberg, Ross, Szeliga,
Taveras, White Holland, Woods, and Woorman
Introduced and read first time: January 31, 2025
Assigned to: Health and Government Operations
Committee Report: Favorable with amendments
House action: Adopted
Read second time: February 27, 2025
CHAPTER ______
1 AN ACT concerning
2 Public Health – Phenibut Consumer Protection Act
3 (JT Alvey Phenibut Consumer Protection Act)
4 FOR the purpose of requiring a retailer that prepares, distributes, sells, or exposes for sale
5 a phenibut product to disclose the factual basis on which any representations
6 regarding the phenibut product are made; establishing prohibitions related to the
7 preparation, distribution, and sale of phenibut products; requiring the Maryland
8 Department of Health, in collaboration with the Maryland Hospital Association, to
9 report to the General Assembly, on or before a certain date, on the number of adverse
10 health events observed in individuals after the use of phenibut; and generally
11 relating to phenibut.
12 BY adding to
13 Article – Health – General
14 Section 21–2F–01 through 21–2F–04 to be under the new subtitle “Subtitle 2F.
15 Phenibut Consumer Protection Act”
16 Annotated Code of Maryland
17 (2023 Replacement Volume and 2024 Supplement)
18 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
19 That the Laws of Maryland read as follows:
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment. *hb0996*

2 HOUSE BILL 996
1 Article – Health – General
2 SUBTITLE 2F. PHENIBUT CONSUMER PROTECTION ACT.
3 21–2F–01.
4 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS
5 INDICATED.
6 (B) “PHENIBUT PRODUCT” MEANS A PRODUCT MARKETED FOR HUMAN
7 CONSUMPTION CONTAINING ANY BETA–PHENYL–GAMMA–AMINOBUTYRIC ACID
8 HCL.
9 (C) (1) “RETAILER” MEANS A PERSON THAT:
10 (I) SELLS, PREPARES, OR MAINTAINS PHENIBUT PRODUCTS;
11 OR
12 (II) ADVERTISES, REPRESENTS, OR HOLDS ITSELF OUT AS
13 SELLING, PREPARING, OR MAINTAINING PHENIBUT PRODUCTS.
14 (2) “RETAILER” INCLUDES A MANUFACTURER, WHOLESALER, STORE,
15 RESTAURANT, HOTEL, CATERING FACILITY, CAMP, BAKERY, DELICATESSEN,
16 SUPERMARKET, GROCERY STORE, CONVENIENCE STORE, GAS STATION, OR FOOD OR
17 DRINK COMPANY.
18 21–2F–02.
19 (A) (1) A RETAILER THAT PREPARES, DISTRIBUTES, SELLS, OR EXPOSES
20 FOR SALE A PHENIBUT PRODUCT SHALL DISCLOSE ON THE PRODUCT LABEL THE
21 FACTUAL BASIS ON WHICH ANY REPRESENTATIONS REGARDING THE PHENIBUT
22 PRODUCT ARE MADE.
23 (2) A RETAILER MAY NOT PREPARE, DISTRIBUTE, SELL, OR EXPOSE
24 FOR SALE A PHENIBUT PRODUCT THAT:
25 (I) DOES NOT COMPLY WITH THE DISCLOSURE REQUIREMENT
26 ESTABLISHED UNDER PARAGRAPH (1) OF THIS SUBSECTION; OR
27 (II) HAS NOT BEEN RECOGNIZED AS A DIETARY INGREDIENT OR
28 APPROVED DRUG BY THE U.S. FOOD AND DRUG ADMINISTRATION.

HOUSE BILL 996 3
1 (B) (1) SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION, A RETAILER
2 MAY NOT PREPARE, DISTRIBUTE, SELL, OR EXPOSE FOR SALE ANY OF THE
3 FOLLOWING:
4 (I) A PHENIBUT PRODUCT THAT IS ADULTERATED WITH A
5 DANGEROUS SUBSTANCE OTHER THAN PHENIBUT;
6 (II) A PHENIBUT PRODUCT THAT IS CONTAMINATED WITH A
7 DANGEROUS SUBSTANCE OTHER THAN PHENIBUT; OR
8 (III) A PRODUCT CONTAINING PHENIBUT THAT DOES NOT
9 INCLUDE ON ITS PACKAGE OR LABEL THE AMOUNT OF
10 BETA–PHENYL–GAMMA–AMINOBUTYRIC ACID HCL CONTAINED IN THE PRODUCT.
11 (2) (I) FOR THE PURPOSE OF PARAGRAPH (1)(I) OF THIS
12 SUBSECTION, A PHENIBUT PRODUCT IS ADULTERATED WITH A DANGEROUS
13 SUBSTANCE OTHER THAN PHENIBUT IF:
14 1. THE PHENIBUT PRODUCT IS MIXED OR PACKED WITH
15 A SUBSTANCE OTHER THAN PHENIBUT; AND
16 2. THAT SUBSTANCE AFFECTS THE QUALITY OR
17 STRENGTH OF THE PHENIBUT PRODUCT TO A DEGREE AS TO RENDER THE PHENIBUT
18 PRODUCT INJURIOUS TO A CONSUMER.
19 (II) FOR THE PURPOSE OF PARAGRAPH (1)(II) OF THIS
20 SUBSECTION, A PHENIBUT PRODUCT IS CONTAMINATED WITH A DANGEROUS
21 SUBSTANCE OTHER THAN PHENIBUT IF THE PHENIBUT PRODUCT CONTAINS A
22 POISONOUS OR OTHERWISE DELETERIOUS INGREDIENT OTHER THAN PHENIBUT,
23 INCLUDING A DRUG THAT IS DESIGNATED AS A CONTROLLED DANGEROUS
24 SUBSTANCE UNDER TITLE 5 OF THE CRIMINAL LAW ARTICLE.
25 (C) A RETAILER MAY NOT DISTRIBUTE, SELL, OR EXPOSE FOR SALE A
26 PHENIBUT PRODUCT TO AN INDIVIDUAL UNDER THE AGE OF 21 YEARS.
27 (D) IN A PROSECUTION FOR A VIOLATION OF THIS SECTION, IT IS A DEFENSE
28 THAT THE DEFENDANT RELIED IN GOOD FAITH ON THE REPRESENTATIONS OF A
29 MANUFACTURER, PROCESSOR, PACKER, OR DISTRIBUTOR OF A PHENIBUT
30 PRODUCT.
31 (E) A RETAILER THAT VIOLATES SUBSECTION (A)(1) OF THIS SECTION IS
32 SUBJECT TO A CIVIL PENALTY NOT EXCEEDING:
33 (1) $1,000 FOR A FIRST VIOLATION; AND

4 HOUSE BILL 996
1 (2) $2,000 FOR EACH SUBSEQUENT VIOLATION.
2 (F) A RETAILER THAT VIOLATES SUBSECTION (A)(2), (B), OR (C) OF THIS
3 SECTION IS GUILTY OF A MISDEMEANOR AND ON CONVICTION IS SUBJECT TO A FINE
4 NOT EXCEEDING $5,000, IMPRISONMENT FOR NOT MORE THAN 90 DAYS, OR BOTH.
5 (G) IN ADDITION TO ANY OTHER PENALTIES SPECIFIED IN THIS SECTION, A
6 RETAILER WHO VIOLATES THIS SECTION IS LIABLE FOR ANY CIVIL DAMAGES
7 SUSTAINED BY THE INDIVIDUAL RESULTING FROM THE VIOLATION.
8 21–2F–03.
9 (A) A RETAILER MAY NOT DIRECTLY OR INDIRECTLY ADVERTISE A
10 THERAPEUTIC BENEFIT OF PHENIBUT.
11 (B) A RETAILER MAY NOT DIRECTLY OR INDIRECTLY ADVERTISE OR
12 MARKET PHENIBUT PRODUCTS TO MINORS.
13 (C) IT IS A VIOLATION OF SUBSECTION (B) OF THIS SECTION FOR A
14 RETAILER TO USE ANY OF THE FOLLOWING IN THE ADVERTISING, PROMOTION,
15 PACKAGING, OR LABELING OF A PHENIBUT PRODUCT:
16 (1) A CARTOON;
17 (2) A SUPERHERO;
18 (3) A VIDEO GAME REFERENCE;
19 (4) AN IMAGE OF A FOOD PRODUCT PRIMARILY INTENDED FOR
20 MINORS;
21 (5) A TRADEMARK THAT IMITATES OR MIMICS THE TRADEMARK OF A
22 PRODUCT THAT HAS BEEN ADVERTISED OR MARKETED PRIMARILY TO MINORS;
23 (6) A SYMBOL OR CELEBRITY THAT IS PRIMARILY ASSOCIATED WITH
24 MINORS OR MEDIA PRIMARILY DIRECTED TO MINORS; AND
25 (7) AN IMAGE OF AN INDIVIDUAL WHO APPEARS TO BE UNDER THE
26 AGE OF 27 YEARS.
27 (D) IT IS A VIOLATION OF SUBSECTION (B) OF THIS SECTION FOR A
28 RETAILER TO ADVERTISE OR PROMOTE A PHENIBUT PRODUCT:

HOUSE BILL 996 5
1 (1) IN A NEWSPAPER, A MAGAZINE, A PERIODICAL, OR ANY OTHER
2 PUBLICATION FOR WHICH INDIVIDUALS UNDER THE AGE OF 21 YEARS CONSTITUTE
3 15% OR MORE OF THE TOTAL AUDIENCE, AS MEASURED BY COMPETENT AND
4 RELIABLE SURVEY EVIDENCE;
5 (2) AT A CONCERT, A STADIUM, A SPORTING EVENT, OR ANY OTHER
6 PUBLIC EVENT FOR WHICH INDIVIDUALS UNDER THE AGE OF 21 YEARS CONSTITUTE
7 15% OR MORE OF THE TOTAL AUDIENCE, AS MEASURED BY COMPETENT AND
8 RELIABLE SURVEY EVIDENCE; OR
9 (3) ON AN OUTDOOR BILLBOARD OR SIGN BOARD THAT IS WITHIN 500
10 FEET OF A SCHOOL.
11 21–2F–04.
12 THE DEPARTMENT SHALL ADOPT REGULATIONS TO CARRY OUT THIS
13 SUBTITLE.
14 SECTION 2. AND BE IT FURTHER ENACTED, That, on or before December 31,
15 2026, the Maryland Department of Health, in collaboration with the Maryland Hospital
16 Association, shall report to the General Assembly, in accordance with § 2–1257 of the State
17 Government Article, on the number of adverse health events observed in individuals after
18 the use of phenibut.
19 SECTION 3. 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
20 October 1, 2025.
Approved:
________________________________________________________________________________
Governor.
________________________________________________________________________________
Speaker of the House of Delegates.
________________________________________________________________________________
President of the Senate.

[DELETED: :CA      5     D B D B P C A C G H H S K K L M M R R R S A P ( F a p p t d t f b o w a r r p r D r h e o i i a t u o p a g r B  A S 2 t 2 t b u t n s “ 2 P  A  (  S T]
[DELETED:  H  A2.PCPA  H O R C  ) N T S T F W H T M ) “PH PT M A P M F HNC A BAPLGAA A –C  ) ( “R”:ER    ) S,,ES PS O M P PS   ) A,IDS RS O H I O AG G ,.   “R”,,R R R ET HL C FY CP BY DN,,,,T E E N ,, ) ( A,, S S S  B O W A R R T P   A,,E E L      )OSN  N )     )IA  O R D.FDA ]
[DELETED: H 3 ) ( S()U  N  N PE DE SL O E F S A O T,   )  P P T I A W A   ) I P P T I C W AT    ) I P C P T D N O I P O L T A OAPLGAA L––HC     () F((O T P O P I O TN A P P I A W A DF     T       S A T Q O   ) F((IO T P O P II O TN A P P I C W A D O T P I T P P C A O O D I O T PT A D T I D A A C D I   R A R5CLA. ) A, R M N DE SL O E F S A  1. ) INN  D OR PR PR O D O A P, ) A()  A      $0N ]
[DELETED:  H      $0 ) A(),(),(  A B  C     S ,90,. ) INN  W V T S I L F A C D )  R M N D O I A AT  ) R M N D O I A O    )I(T I A V O S BO T S F A T U A O T F I T AG PNG     A;   A;   A;    I O A F P P I F      S      7.   )I(T I A V O S BO T S F A ]
[DELETED: H 5   I,, A NR A ME A PL O A  %O M O T T AE A M B C A   A,,T M T   %O M O T T AE A M B C AE    O5   E S A R T C O T  S 2 A G t  S O          G               ]